Beigene (NASDAQ:ONC) Issues Quarterly Earnings Results, Misses Expectations By $0.55 EPS

Beigene (NASDAQ:ONC - Get Free Report) released its earnings results on Thursday. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55), Zacks reports. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.13 billion during the quarter, compared to analysts' expectations of $1.09 billion. Beigene updated its FY 2025 guidance to EPS.

Beigene Price Performance

NASDAQ:ONC traded down $26.27 on Monday, reaching $245.53. 1,291,907 shares of the company's stock were exchanged, compared to its average volume of 443,150. The firm has a market capitalization of $24.03 billion, a PE ratio of -29.80, a P/E/G ratio of 7.73 and a beta of 0.63. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. Beigene has a 52 week low of $126.97 and a 52 week high of $287.88.

Insider Activity

In related news, Director Bros. Advisors Lp Baker sold 732,827 shares of the stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now owns 730,642 shares of the company's stock, valued at approximately $189,966,920. This represents a 50.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Xiaobin Wu sold 21,267 shares of the firm's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69. The disclosure for this sale can be found here. Insiders have sold a total of 790,950 shares of company stock valued at $204,616,547 over the last quarter. Company insiders own 7.43% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms recently commented on ONC. Bank of America raised shares of Beigene from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $207.00 to $320.00 in a report on Monday. Macquarie boosted their target price on Beigene from $259.00 to $313.00 and gave the company an "outperform" rating in a research note on Friday.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.